Skip to content

Effects of Krill Oil on Intestinal Integrity Markers in Elite Rowers.

Krill Oil Supplementation and Its Effect on Intestinal Permeability Markers in Elite Rowers.

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06271434
Enrollment
30
Registered
2024-02-21
Start date
2024-03-23
Completion date
2024-06-24
Last updated
2024-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endothelial Dysfunction

Keywords

endotoxin, gastrointestinal symtoms, gut permeability

Brief summary

The study aims to check the influence of krill oil on markers of intestinal injury and intoxication. Research group: the research will be conducted in a homogeneous group of professional rowers (N=30), all competitors qualified for the Polish Youth Rowing Team, aged 18 - 24. The sample size was confiremed in statistical analyses. Rowing performance test will be conducted at the beginning and at the end of the training camp. Participants will perform a test on a rowing ergometer (Concept II, USA); each subject will have to cover a distance of 2000 m in the shortest possible time which is the distance starting in rowing competitions. The results of both tests will be considered in the selection for the championship team; therefore, athletes will be well motivated to perform both tests with maximum effort. Hypotesis: The krill oil will infleunce the gut barier integrity.

Detailed description

All competitors will be randomly divided into two groups (double-blind): A. supplemented (n = 15), who will receive one capsule of THYROX (Atlantic krill oil) four times a day. B. control (n = 15) receiving placebo. The supplementation period will be six weeks. Characteristic of the supplement: THYROX (Atlantic krill oil). The daily recommended intake of krill oil is 2000 mg, which includes 350 mg of omega-3 fatty acids, 240 mg of EPA, 110 mg of DHA, 800 mg of phospholipids, and 200 mg of astaxanthin. Placebo will be produced by MLB Bitrade Sp. z o.o., Poznan. Measurement: The project contractors will measure all parameters using the available equipment in the ZWKF laboratory in Gorzów Wielkopolski and commercial assay kits. Polyethylene clotting activator tubes (9 ml) will be centrifuged to separate the morphotic elements from the serum using a centrifuge (3000 rpm for 10 min). The serum will be pipetted into several Eppendorf tubes, then frozen (temp. -80 °C). All the following biochemical parameters will be determined from the extracted serum: using the ELISA method by the test manufacturer's instructions. The designations include the flowing parameters: a food diary will be filled day before the study and in the morning before the test, markers of gut injury: I-FABP (intestinal fatty acid binding protein), CLDN-3 (claudin 3) intoxication: LBP (lipopolysaccharide binding protein) stress hormones: ACTH and cortisol will be determined using the colourimetric method on the SPECTROstar Nano reader. The lactate (La) concentration will be determined from the capillary blood immediately after collection using a commercially available kit (Diaglobal, Germany).

Interventions

DIETARY_SUPPLEMENTTHYROX (Atlantic krill oil

The daily content of krill oil is 2000 mg, including omega-3 fatty acids 350 mg, EPA - 240 mg, DHA- 110 mg, phospholipids - 800 mg, astaxanthin 200 mg.

DIETARY_SUPPLEMENTPlacebo

The control capsules will be made of olive oil of equal size and color.

Sponsors

Poznan University of Physical Education
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Masking description

Triple

Intervention model description

All competitors will be randomly divided into two groups (double-blind): A. supplemented (n = 15), who will receive one capsule of a supplement called THYROX (Atlantic krill oil) four times a day. B. control (n = 15) receiving placebo. The supplementation period will be six weeks.

Eligibility

Sex/Gender
ALL
Age
18 Years to 24 Years
Healthy volunteers
Yes

Inclusion criteria

* training experience of a minimum of five years, * minimum training time per week 240 minutes, * all competitors qualified for the Polish Youth Rowing Team, * completing a food diary, * finishing 2000m ergometer test.

Exclusion criteria

* Probiotics, prebiotics and antibiotic therapy within the last three months, * dietary regime, * gastrointestinal diseases, * lactose intolerance.

Design outcomes

Primary

MeasureTime frameDescription
I-FABP (intestinal fatty acid binding protein)Blood samples will be taken from the cubital vein at three-time points: before each stress test (after overnight fasting), one minute after the end of the test, and after a 3-hour recovery period.gut injury (enterocyte)
CLDN-3Blood samples will be taken from the cubital vein at three-time points: before each stress test (after overnight fasting), one minute after the end of the test, and after a 3-hour recovery period.gut injury (tight junction)
LBP (lipopolysaccharide binding protein)Blood samples will be taken from the cubital vein at three-time points: before each stress test (after overnight fasting), one minute after the end of the test, and after a 3-hour recovery period.endotoxin
Catechyloamines, cortisolBlood samples will be taken from the cubital vein at three-time points: before each stress test (after overnight fasting), one minute after the end of the test, and after a 3-hour recovery period.stress hormones
CD14Blood samples will be taken from the cubital vein at three-time points: before each stress test (after overnight fasting), one minute after the end of the test, and after a 3-hour recovery period.endotoxin

Secondary

MeasureTime frameDescription
Food intakeday before the test, morning before the testmacro and micronutrients, fluids

Contacts

Primary ContactHanna Dziewiecka, Msc
hannadziewiecka@gmail.com606880282
Backup ContactAnna Skarpańska-Stejnborn, professor

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026